Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Opevesostat With and Without Itraconazole in Healthy Adult Males
NCT07548606Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of opevesostat in prostate cancer (PCa) (2 arms), sponsored by Merck & Co. Primary endpoints: Area under the concentration versus time curve from 0 to infinity, Area under the concentration versus time curve from 0 to last quantifiable sample and 5 more. Started May 2026; status: completed.
02
Drugs
opevesostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07548606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07548606.